Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as
treatment prior to surgery with radical cystectomy for bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
AstraZeneca Cross Cancer Institute Hamilton Health Sciences Corporation London Health Sciences Centre Ontario Institute for Cancer Research Ozmosis Research Inc.